Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.

Kan KikuchiMasaomi NangakuMunekazu RyuzakiTomoyuki YamakawaYoshihiro OtaNorio HanafusaKen SakaiYoshihiko KannoRyoichi AndoToshio ShinodaShu WakinoHidetomo NakamotoYoshiaki TakemotoTadao Akizawanull null

Published in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2023)

Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important.

Keyphrases

clinical practice
sars cov
chronic kidney disease
coronavirus disease
end stage renal disease
peritoneal dialysis